Energizer Holdings $950 million refinancing
Davis Polk advised (i) the joint lead arrangers and joint bookrunners and (ii) the administrative agent, in connection with a $550 million senior secured term loan facility and a $400…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid Biosciences Inc. of $90 million of common stock.
Solid Biosciences Inc…
Ormat Technologies $307 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $307 million public offering of 4,150,000 shares of common stock…
Veritiv secondary offering
Davis Polk advised the underwriter in connection with an SEC-registered secondary offering of 1,400,000 shares of Veritiv Corporation’s common stock by UWW Holdings, LLC. The common…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…
Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…
loanDepot $500 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with the debut Rule 144A/Regulation S offering by LD Holdings Group LLC of $500 million aggregate principal…
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…
Biondvax Pharmaceuticals $100 million at-the-market offering
Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …